Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug's efficacy in advanced non-small cell lung cancer (NSCLC).

Related collections

Author and article information

Journal

Title: JAMA Oncology

Abbreviated Title: JAMA Oncol

Publisher: American Medical Association (AMA)

ISSN (Print): 2374-2437

Publication date Created: November 01 2018

Publication date (Print): November 01 2018

Volume: 4

Issue: 11

Page: 1569

Affiliations

[1 ]Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China

[2 ]Department of Thoracic Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China

[3 ]Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

[4 ]Henan Cancer Hospital, Zhengzhou, China

[5 ]Department of Respiratory Diseases, Peking Union Medical College Hospital, Beijing, China

[6 ]Department of Oncology, Linyi Cancer Hospital, Linyi, China

[7 ]Department of Internal Medicine-Oncology, Shandong Cancer Hospital, Jinan, China

[8 ]Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China

[9 ]Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

[10 ]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

[11 ]Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China

[12 ]Department of Pulmonary Medicine, Lanzhou Military General Hospital, Lanzhou, China

[13 ]Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China

[14 ]Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China

[15 ]Department of Medicine I, Medical University of Vienna, Vienna, Austria

[16 ]Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China

[17 ]Department of Respiratory Diseases, Tang Du Hospital, Xi’an, China

[18 ]First Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, China

[19 ]Department of General Medicine, Capital Medical University, Beijing Chest Hospital, Beijing, China

Article

DOI: 10.1001/jamaoncol.2018.3039

PMC ID: 6248083

PubMed ID: 30098152

SO-VID: 6a6744fb-1285-4920-a6e4-7a76c409245b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 295

See all cited by

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer : The ALTER 0303 Phase 3 Randomized Clinical Trial

Read this article at